This section provides general corporate and group information about Pharvaris N.V. and its subsidiaries.

The consolidated financial statements of Pharvaris N.V. (the “Company” or “Pharvaris”) and its subsidiaries (collectively, “The Group”) for the year ended December 31, 2021 were authorized for issue in accordance with a resolution of the directors on March 29, 2022.

Pharvaris N.V. was incorporated on September 30, 2015 and is based in Leiden, the Netherlands. The Company’s registered office is located at J.H. Oortweg 21, Leiden. The Company has been registered at the Chamber of Commerce under file number 64239411.

Pharvaris is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases.

			% of equity interest
Name	Legal seat	Country of incorporation	2021			2020
Pharvaris Holdings B.V.	Leiden	The Netherlands		100	%		100	%
Pharvaris Netherlands B.V.	Leiden	The Netherlands		100	%		100	%
Pharvaris, Inc.	Delaware	United States of America		100	%		100	%
Pharvaris GmbH	Zug	Switzerland		100	%		100	%

Pharvaris, Inc. and Pharvaris GmbH were incorporated on January 31, 2020 and March 27, 2020 respectively. Pharvaris, Inc. acts as a service provider to the principal Company of the Group. Pharvaris GmbH is the principal Company of the Group starting April 1, 2020. The principal Company faces the market/external parties and makes all operational group decisions.

The ultimate parent company of the Group is Pharvaris N.V., which is based in the Netherlands.